Medical Devices US

US Neuromodulation for Depression Market Analysis, 2024–2034

US Neuromodulation for Depression Market Industry Trends and Forecast to 2034: Segmented by (Technology, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034

Overview

Market Dashboard

US · 2024–2034 · estimates

Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.

Estimate 2024 $519.9 Mn Estimated value
Estimate 2025 $560.5 Mn 35.6% of the global market
Projected 2034 $1.10 Bn 96.6% Adds $541.4 Mn over 9 forecast years
CAGR 2025–2034 7.8% Faster than 58% of 173 Medical Devices markets here
Key players 5
  • US is 35.63% of the global market.
  • In North America, the largest is US (this report) at $560.5 Mn.
  • Fastest growing: Canada at 10.1% a year.
  • US ranks 1st of 2 by size in North America.

Market size projection

US

Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.

Value added each year

$541.4 Mn total, 2026–2034

Year-by-year market size, 2024–2034
Neuromodulation for Depression Market market size by year, US
YearMarket sizeChange that yearSince 2025
2024 (estimate) $519.9 Mn — —
2025 (base) $560.5 Mn +$40.6 Mn —
2026 (forecast) $604.2 Mn +$43.7 Mn +7.8%
2027 (forecast) $651.3 Mn +$47.1 Mn +16.2%
2028 (forecast) $702.1 Mn +$50.8 Mn +25.3%
2029 (forecast) $756.9 Mn +$54.8 Mn +35%
2030 (forecast) $815.9 Mn +$59.0 Mn +45.6%
2031 (forecast) $879.6 Mn +$63.6 Mn +56.9%
2032 (forecast) $948.2 Mn +$68.6 Mn +69.2%
2033 (forecast) $1.02 Bn +$74.0 Mn +82.4%
2034 (forecast) $1.10 Bn +$79.7 Mn +96.6%

Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.

Same market worldwide

By geography

  1. Global $1.57 Bn
  2. North America $807.4 Mn
  3. US (this report) $560.5 Mn
  4. Europe $298.1 Mn
  5. APAC $303.5 Mn
  6. China $119.2 Mn
  7. Canada $113.0 Mn
  8. Japan $104.5 Mn
  9. Latin America $73.3 Mn
  10. Middle East $62.8 Mn
  11. Germany $49.4 Mn
  12. UK $45.0 Mn
  13. France $36.7 Mn
  14. Brazil $35.9 Mn
  15. Italy $33.2 Mn
  16. Spain $32.4 Mn
  17. India $30.1 Mn
  18. Ecuador $28.2 Mn
  19. Saudi Arabia $26.3 Mn
  20. Africa $25.6 Mn
  21. Mexico $23.9 Mn
  22. Australia $17.3 Mn
  23. New Zealand $15.6 Mn
  24. Russia $15.8 Mn
  25. South Africa $9.7 Mn
  26. UAE $8.0 Mn
  27. Egypt $4.5 Mn
  28. Philippines $3.4 Mn
  29. Hong Kong $2.6 Mn
  30. Malaysia $2.4 Mn
  31. Singapore $2.1 Mn
  32. Thailand $1.7 Mn
  33. Kenya $1.2 Mn

The US Neuromodulation for Depression Market Analysis Executive Summary

Neuromodulation for depression uses magnetic or electrical stimulation of the brain, such as TMS, to treat depression that does not respond to medicines.

Key segments of the neuromodulation for Depression market include technology (Transcranial Magnetic Stimulation, Electroconvulsive Therapy and Vagus Nerve Stimulation) and setting (Clinics, Hospitals and Home).

US Neuromodulation for Depression Market Dynamics

Market Growth Drivers

More people seeking help for mental health, less stigma, better screening and new treatments with faster effects are driving the neuromodulation for Depression market. Governments and employers are investing more in mental health care.

Opportunity

Digital tools, new drug classes and care built into primary care and workplaces give the neuromodulation for Depression market strong room to grow worldwide.

Market Restraints

Shortages of mental health professionals, limited insurance coverage, side effects and the need for long-term treatment hold back the neuromodulation for Depression market.

Competitive Landscape for Neuromodulation for Depression Market in US

The neuromodulation for Depression market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.

Key Players

Healthcare Policies and Regulatory Landscape for Neuromodulation for Depression Market in US

Policy changes and Reimbursement scenario

Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how neuromodulation for Depression products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in US.

Beyond the market numbers

Research, trials and patients

What doctors and scientists are doing in Neuromodulation for Depression right now, from free public sources.

Clinical trials

209 active trials in the US

Recruiting, about to start, or running now.

Top trial sponsors (worldwide)

  1. Magnetic Tides 2 active trials on ClinicalTrials.gov (opens in a new tab)

Source: ClinicalTrials.gov, Industry lead sponsors of active studies found with this market's trial search, worldwide. Retrieved 13 Nov 2026.

See every trial on ClinicalTrials.gov (opens in a new tab)

Latest research 74 papers since 2021 (worldwide)

  1. Subgenual Cingulate Functional Connectivity Predicts Neuromodulation Response in Depression: A Systematic Review. Biological psychiatry global open science, 2026
  2. Neuromodulation Therapies for Depression: Current Status and Future Directions. Alpha psychiatry, 2026
  3. Depressive phenotype shapes behavioral, neuroendocrine and molecular responses to repetitive transcranial magnetic stimulation in preclinical models of depression. Frontiers in molecular neuroscience, 2026
  4. Underuse of neuromodulation in depression care - Authors' reply. Lancet (London, England), 2026
  5. Underuse of neuromodulation in depression care. Lancet (London, England), 2026
Search all of them on PubMed (opens in a new tab)

Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.

Public data, with sources

Neuromodulation for Depression in context

The US compared

  • Health spending per person: 13,473 US$ per person (2023). World: 1,317 US$ per person (2023).[1]
  • Doctors: 3.68 per 1,000 people (2022). World: 1.86 per 1,000 people (2022).[2]
  • People aged 65 and over: 18.4% of people (2025). World: 10.4% of people (2025).[3]

Questions, answered with public data

How many clinical trials on Neuromodulation for Depression are running in the US?
209 studies are recruiting, active or about to start in the US.[4]
How much research is published on Neuromodulation for Depression?
PubMed lists 74 papers added since January 2021 that match this market, worldwide.[5]

[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 13 Nov 2026.

[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 13 Nov 2026.

[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 13 Nov 2026.

[4] ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in the US. Retrieved 12 Nov 2026.

[5] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.

Free data on this topic

Get a free sample The table of contents and sample pages. No payment needed. Request sample Consult Us Questions about Neuromodulation for Depression in US? Our analysts can size it for your plan. Talk to us See the public data Health figures for every country, free. Open the Public Health Dashboard

From our blog

Adaptogens: Ancient Herbs, Modern Market170 WHO Member States report the use of traditional medicine. Adaptogens like ashwagandha, rhodiola and… Stress and Mood Supplements: Ashwagandha and BeyondDepression and anxiety cost the world about US$1 trillion a year. Ashwagandha has some evidence for stress… Brain Cancer Diagnosis: Imaging and New BiomarkersAbout 321,000 people were diagnosed with brain and nervous system tumours in 2022, and about 248,000 died…
Back to Catalogue
Keep exploring

Related Medical Devices reports in US

See all
Same topic, other categories

Related on mental health and brain and nerves

See the topic